Currently, the fundamental treatment for ischemic stroke is tissue-type plasminogen activator (tPA) thrombolysis or combined with endovascular thrombectomy aimed at restoring reperfusion and improving recanalization rates in a timely and effective manner, but the narrow therapeutic window, risk of complications, and limited therapeutic efficacy limit access to treatment to only a small number of patients (National Institute of Neurological, D., and Stroke rt, P.A.S.S.G, 1995; Liu et al., 2023; She et al., 2023). This evidence concerns the gene PLAT and ischemic stroke.